SCHEMBL4428095

SCHEMBL4428095

CCOc1ccccc1C(=O)Nc1ccc(F)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.77
KMT2A Q03164 4/20 0.77
RAB9A P51151 3/20 0.73
MAPT P10636 4/20 0.69
MAPK1 P28482 2/20 0.67
HSD17B10 Q99714 1/20 0.67
NPC1 O15118 1/20 0.67
TP53 P04637 1/20 0.67
SMN1; SMN2 Q16637 1/20 0.67
RECQL P46063 1/20 0.65
KCNK3 O14649 2/20 0.65
KCNK9 Q9NPC2 2/20 0.65
RXFP1 Q9HBX9 2/20 0.64
PKM P14618 1/20 0.64
GAA P10253 1/20 0.62
ATM Q13315 1/20 0.62
NPSR1 Q6W5P4 1/20 0.62
GPR55 Q9Y2T6 1/20 0.62
HCRTR1 O43613 1/20 0.61
LMNA P02545 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5504642 0.89 MEN1 (0.83) MEN1KMT2ARAB9AMAPTMAPK1
SCHEMBL4432149 0.88 RAB9A (0.84) MEN1KMT2ARAB9AMAPTMAPK1
SCHEMBL15285364 0.84 PKM (0.70) MEN1KMT2AMAPTSMN1; SMN2RECQL
SCHEMBL4429130 0.83 MAPT (0.71) MEN1KMT2ARAB9AMAPTMAPK1
SCHEMBL30739719 0.83 MAPT (0.71) MEN1KMT2ARAB9AMAPTMAPK1
SCHEMBL22323774 0.82 MEN1 (0.67) MEN1KMT2ARAB9AMAPTMAPK1
SCHEMBL15285704 0.81 RECQL (0.78) MEN1KMT2AMAPTSMN1; SMN2RECQL
SCHEMBL2703394 0.81 LMNA (0.62) MEN1KMT2ARAB9AMAPTHSD17B10
SCHEMBL27348350 0.80 LMNA (0.66) MEN1KMT2ARAB9AMAPTNPC1
SCHEMBL15540178 0.80 PKM (0.57) MEN1KMT2ARAB9AMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9447027-B2 Treating long QT syndrome THE GENERAL HOSPITAL CORPORATION (US) 2016-09-20 US disclosed
US-9447027-B2 Treating long QT syndrome THE GENERAL HOSPITAL CORPORATION (US) 2016-09-20 US disclosed
US-20130310351-A1 Treating Long QT Syndrome THE GENERAL HOSPITAL CORPORATION (US) 2013-11-21 US disclosed
WO-2012054718-A2 TREATING LONG QT SYNDROME THE GENERAL HOSPITAL CORPORATION (US) 2012-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130310351-A1 Treating Long QT Syndrome TNNI3, TNNT2, TNNC1 MEN1 2802/4885KMT2A 2707/4885RAB9A 1007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.